tetano
Editor, Senior Moderator
Sci Rep
. 2024 Oct 14;14(1):23974.
doi: 10.1038/s41598-024-74502-5. Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing
Huaiya Xie[SUP] #[/SUP][SUP] 1 [/SUP], Yaqi Wang[SUP] #[/SUP][SUP] 1 [/SUP], Yan Xu[SUP] 1 [/SUP], Luo Wang[SUP] 1 [/SUP], Junping Fan[SUP] 1 [/SUP], Siqi Pan[SUP] 1 [/SUP], Chuan Shi[SUP] 1 [/SUP], Xiaoyan Liu[SUP] 1 [/SUP], Xiaoxing Gao[SUP] 1 [/SUP], Xiaobei Guo[SUP] 1 [/SUP], Siyuan Yu[SUP] 1 [/SUP], Jia Liu[SUP] 1 [/SUP], Dongming Zhang[SUP] 1 [/SUP], Yanli Yang[SUP] 1 [/SUP], Hong Zhang[SUP] 1 [/SUP], Jinglan Wang[SUP] 1 [/SUP], Aohua Wu[SUP] 1 [/SUP], Xueqi Liu[SUP] 1 [/SUP], Jihai Liu[SUP] 2 [/SUP], Huadong Zhu[SUP] 2 [/SUP], Xiang Zhou[SUP] 3 [/SUP], Xinlun Tian[SUP] 4 5 [/SUP], Mengzhao Wang[SUP] 6 7 [/SUP]
Affiliations
The study was to evaluate the clinical outcomes of azvudine versus nirmatrelvir-ritonavir against omicron strains of coronavirus disease 2019 infections and determine their comparative effectiveness. This retrospective study included 716 patients who received nirmatrelvir-ritonavir (NR group) or azvudine (FNC group) at Peking Union Medical College Hospital between 1 November 2022 and 27 February 2023. Patients in the FNC group (n = 304) were younger, exhibited less severe symptoms, started antiviral therapy later, received corticosteroids more frequently, and used tocilizumab less frequently than patients in the NR group (n = 412). Within 28 d of therapy, 40 (9.7%) and 20 (6.6%) deaths were in the NR and FNC groups, respectively. No differences were observed between drugs and mortality rates (odds ratio [OR] 0.78, 95% CI 0.40-1.5, P = 0.45), clinical improvement (OR 0.79, 95% CI 0.79-1.3, P = 0.38), and clinical progression (OR 1.0, 95% CI 0.58-1.8, P = 0.96). More patients in the NR group experienced platelet decline than those in the FNC group (17.6% vs. 8.9%, P = 0.034). This study indicated that the effectiveness and safety of azvudine were comparable to those of nirmatrelvir-ritonavir.
Keywords: Azvudine; Coronavirus disease 2019; Mortality; Nirmatrelvir-ritonavir; Seven-category ordinal scale.
. 2024 Oct 14;14(1):23974.
doi: 10.1038/s41598-024-74502-5. Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing
Huaiya Xie[SUP] #[/SUP][SUP] 1 [/SUP], Yaqi Wang[SUP] #[/SUP][SUP] 1 [/SUP], Yan Xu[SUP] 1 [/SUP], Luo Wang[SUP] 1 [/SUP], Junping Fan[SUP] 1 [/SUP], Siqi Pan[SUP] 1 [/SUP], Chuan Shi[SUP] 1 [/SUP], Xiaoyan Liu[SUP] 1 [/SUP], Xiaoxing Gao[SUP] 1 [/SUP], Xiaobei Guo[SUP] 1 [/SUP], Siyuan Yu[SUP] 1 [/SUP], Jia Liu[SUP] 1 [/SUP], Dongming Zhang[SUP] 1 [/SUP], Yanli Yang[SUP] 1 [/SUP], Hong Zhang[SUP] 1 [/SUP], Jinglan Wang[SUP] 1 [/SUP], Aohua Wu[SUP] 1 [/SUP], Xueqi Liu[SUP] 1 [/SUP], Jihai Liu[SUP] 2 [/SUP], Huadong Zhu[SUP] 2 [/SUP], Xiang Zhou[SUP] 3 [/SUP], Xinlun Tian[SUP] 4 5 [/SUP], Mengzhao Wang[SUP] 6 7 [/SUP]
Affiliations
- PMID: 39402091
- DOI: 10.1038/s41598-024-74502-5
The study was to evaluate the clinical outcomes of azvudine versus nirmatrelvir-ritonavir against omicron strains of coronavirus disease 2019 infections and determine their comparative effectiveness. This retrospective study included 716 patients who received nirmatrelvir-ritonavir (NR group) or azvudine (FNC group) at Peking Union Medical College Hospital between 1 November 2022 and 27 February 2023. Patients in the FNC group (n = 304) were younger, exhibited less severe symptoms, started antiviral therapy later, received corticosteroids more frequently, and used tocilizumab less frequently than patients in the NR group (n = 412). Within 28 d of therapy, 40 (9.7%) and 20 (6.6%) deaths were in the NR and FNC groups, respectively. No differences were observed between drugs and mortality rates (odds ratio [OR] 0.78, 95% CI 0.40-1.5, P = 0.45), clinical improvement (OR 0.79, 95% CI 0.79-1.3, P = 0.38), and clinical progression (OR 1.0, 95% CI 0.58-1.8, P = 0.96). More patients in the NR group experienced platelet decline than those in the FNC group (17.6% vs. 8.9%, P = 0.034). This study indicated that the effectiveness and safety of azvudine were comparable to those of nirmatrelvir-ritonavir.
Keywords: Azvudine; Coronavirus disease 2019; Mortality; Nirmatrelvir-ritonavir; Seven-category ordinal scale.